AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.05

+1.7%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$898.69M
EPS-1.7400
P/E Ratio-5.20
Earnings Date08/12/2026

spry

Revenue

Last Annual Value

84.28M

3-Year CAGR

300%

5-Year CAGR

36%

10-Year CAGR

%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Revenue

SPRY · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
84.28M
1311.0%72.6%N/A 
14.08M
-8.1%5.1%25.1%
SVRA logo
Savara Inc.
NASDAQ:SVRA
0.00
N/AN/AN/A
67.48M
N/AN/AN/A
0.00
N/AN/AN/A
19.09M
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
893.00K
N/AN/AN/A
0.00
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.05, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.05